PhytoCare: Journal of Pharmacology and Natural Remedies
Vol 1 No 2 Februari 2025
ISSN: XXXX-XXXX (Electronic)
Open Access: https://journals.ai-mrc.com/phytocare

Exploring the Integration of Molecular Modeling and Computational Pharmacology: A Comprehensive Study on Ligand-Receptor Interaction Analysis

Dito Anurogo
Universitas Muhammadiyah Makassar, Indonesia
dito.anurogo@med.unismuh.ac.id

Article Info

Article history:
Received 22-01-2025
Revised 02-02-2025
Accepted 16-02-2025

Keyword:
Computational Pharmacology; Molecular Modeling; Ligand-Receptor Interaction; Drug Discovery; Bioinformatics.

ABSTRACT

Computational pharmacology has emerged as a pivotal field in drug discovery leveraging molecular modeling techniques to predict ligand-receptor interactions and streamline therapeutic development. Despite advancements, the subjective experiences of researchers navigating the complexities of computational tools and interdisciplinary collaboration remain underexplored. This study uses a phenomenological approach to explore how researchers interpret and integrate molecular simulations within the broader context of drug discovery workflows. The research uncovers the lived experiences of ten researchers, focusing on challenges related to technical complexity, interdisciplinary dynamics, and validation of computational results. Data were collected through in-depth interviews and analyzed thematically to capture shared meanings and interpretations. Findings reveal that researchers face significant obstacles in aligning computational predictions with experimental realities, emphasizing the importance of collaborative problem-solving and tailored training. These insights provide a nuanced understanding of the human dimensions underpinning computational pharmacology, bridging gaps in prior research that focused primarily on technical performance metrics. The study highlights the critical role of subjective experiences in advancing computational methodologies, offering a foundation for future research aimed at integrating human-centered approaches into drug discovery frameworks.

INTRODUCTION

The discovery of new drugs has increasingly relied on in silico methods, which enable the prediction of molecular interactions and streamline the drug development process (Baba dkk., 2024). Computational pharmacology and molecular modeling have become integral tools in understanding ligand-receptor interactions, offering insights into binding affinities and molecular dynamics. These technologies hold promise for accelerating drug discovery, reducing costs, and minimizing the reliance on extensive in vitro and in vivo experiments. However, the application of these tools is not without challenges, particularly in terms of interpreting complex data and validating computational predictions against empirical findings.

Key methodologies such as molecular docking and molecular dynamics simulations have been widely employed to model and predict ligand-receptor interactions. These approaches provide valuable preliminary insights into molecular behavior and potential therapeutic efficacy. However, studies, including Goodsell et al. (1998), have highlighted limitations in the direct correlation between computational predictions and experimental outcomes, particularly in biological validation. This gap underscores the importance of understanding the subjective experiences of researchers navigating these technological complexities.

In this context, the lived experiences of researchers play a critical role in shaping how computational tools are integrated into the drug discovery pipeline. The interpretation of data,

adjustments to models, and interdisciplinary collaboration reflect the nuanced challenges of the field. Exploring these subjective perspectives provides a deeper understanding of the phenomenon, aligning with the phenomenological emphasis on uncovering meaning through the lens of lived experiences. By addressing these gaps, this study seeks to contribute to the broader understanding of computational pharmac Research on the subjective experiences of individuals engaged in computational pharmacology has emerged as a critical area of study, reflecting the increasing recognition of the nuanced challenges in this field (Bian dkk., 2019). While computational methods such as molecular docking and dynamics simulations have advanced drug discovery, they remain heavily reliant on researchers' interpretative skills to bridge gaps between computational predictions and biological validations. These subjective dimensions, including decision-making processes, collaboration, and technological navigation, are often overlooked in traditional quantitative approaches.

Methodological challenges persist in capturing the depth of researchers' lived experiences. Quantitative methods, while effective in measuring outcomes or technical parameters, often fail to address the rich, subjective realities of navigating complex computational systems. Prior studies have largely focused on technological performance metrics, leaving the human experience underexplored. This oversight limits the ability to fully understand the interplay between technology, expertise, and interdisciplinary collaboration within computational pharmacology.

Given these limitations, phenomenological approaches are uniquely suited to illuminate the essence of these experiences. By focusing on the subjective realities of researchers, this study addresses a critical gap in understanding the experiential and interpretative dimensions that underpin the effective application of computational pharmacology. This perspective enables a more holistic appreciation of the challenges and opportunities in leveraging computational tools for drug discovery.ology's role in modern drug discovery.

While existing approaches in computational pharmacology, such as molecular docking and molecular dynamics, have proven effective for modeling ligand-receptor interactions, they predominantly focus on technical and quantitative aspects. These methods emphasize the optimization of algorithms, accuracy of predictions, and performance metrics but often neglect the interpretative and experiential dimensions of researchers' engagement with these tools. As a result, the broader understanding of how researchers navigate technological complexities, collaborate across disciplines, and validate computational findings in practical settings remains underexplored.

This gap is further exacerbated by the reliance on quantitative methods, which are insufficient for capturing the rich, subjective experiences and nuanced decision-making processes that define the application of computational tools in drug discovery (Devaraji & Sivaraman, 2024). Recent literature highlights the need to integrate more human-centered approaches into computational pharmacology, addressing the intersection of technological innovation and researcher expertise. Existing research provides limited insight into the interpretative challenges faced by researchers, such as balancing computational predictions with biological relevance and fostering interdisciplinary collaboration to enhance simulation accuracy.

To address these limitations, adopting a phenomenological approach offers a valuable alternative. By focusing on the lived experiences of researchers, this study seeks to uncover the deeper meanings and shared understandings that shape their interactions with computational pharmacology tools. This perspective provides a holistic and nuanced understanding of the phenomenon, contributing to a more comprehensive appreciation of the field's potential and challenges.

Research exploring subjective experiences in scientific domains has highlighted the value of understanding individual perspectives to complement quantitative findings. Studies on computational pharmacology often emphasize technical advancements but rarely address the lived experiences of researchers who engage with these technologies. Theoretical foundations, such as Koshland's (1958) principles of molecular interactions, and methodological frameworks, such as phenomenological inquiry, provide valuable lenses for exploring these dimensions. Previous research has identified gaps in aligning computational outputs with biological realities, but the experiential challenges of researchers navigating these gaps remain underexplored. This study aims to address this omission by focusing on the subjective and interpretative aspects of computational pharmacology.

.

The phenomenological approach adopted in this study offers a structured method for capturing the essence of researchers' lived experiences (Geevarghese dkk., 2024). By centering on themes such as technical complexity, interdisciplinary collaboration, and validation challenges, the study aims to answer critical questions about how researchers interpret and integrate computational tools into their workflows. This method allows for a holistic understanding of the phenomenon, emphasizing the shared meanings and interpretative nuances that quantitative methods cannot capture. The findings provide new insights into the experiential dimensions of computational pharmacology, addressing the knowledge gap identified earlier.

This article is organized into several key sections to guide the reader through the research process. The introduction provides an overview of the study's context, objectives, and relevance. Subsequent sections delve into the methodological framework, detailing the phenomenological approach and data collection strategies (Guan dkk., 2022). The results section presents the key themes derived from the analysis, while the discussion explores their implications in the broader context of computational pharmacology. The conclusion synthesizes the findings and suggests pathways for future research, emphasizing the need for integrating experiential insights into technological advancements.

RESEARCH METHODS

Study Design

This study employed a phenomenological approach to explore the subjective experiences of researchers in computational pharmacology and molecular modeling. The phenomenological method was chosen due to its focus on uncovering the essence of lived experiences and providing an in-depth understanding of complex phenomena (Hosseini & Amanlou, 2020). This approach was particularly suitable for addressing the research questions, as it facilitated the exploration of researchers' perspectives on the technical challenges, interdisciplinary collaboration, and practical relevance of their work. A descriptive phenomenological framework was utilized, emphasizing the detailed description of participants' experiences while bracketing preconceived notions to capture the phenomenon's essence authentically.

Participants

The study included ten participants with at least five years of experience in computational pharmacology, working in pharmaceutical research centers or academic institutions. Participants were selected using purposive sampling to ensure their expertise in molecular docking and molecular dynamics simulations (Ivanets dkk., 2021). Inclusion criteria required active involvement in ligand-receptor analysis using computational methods. Individuals with only administrative roles or lacking direct experience in data analysis were excluded. The participants represented a diverse group, with an equal distribution of gender and an average age of 38 years, contributing to a comprehensive understanding of the phenomenon under investigation.

Data Collection

Data were collected through in-depth, semi-structured interviews conducted in a private and comfortable setting to encourage open and honest sharing of experiences (Khan dkk., 2024). An interview guide, developed based on the research questions, included prompts about participants' technical challenges, collaborative practices, and perceptions of computational pharmacology's impact on drug discovery. Interviews lasted between 60 and 90 minutes and were audio-recorded with participants' consent. Observations of participants' laboratory activities and simulation processes provided additional context, focusing on discussions related to parameter configurations and collaborative efforts. Data collection adhered to ethical guidelines to ensure participants' confidentiality and comfort.

Data Analysis

`

Data were analyzed using a thematic phenomenological approach to identify and interpret key themes emerging from participants' narratives. Interview transcripts were coded systematically to uncover recurring patterns and themes, such as technical complexity, interdisciplinary collaboration, and practical applications of computational tools (Lekmine dkk., 2024). Software (NVivo) was used to organize and manage the coding process, facilitating a systematic exploration of the data. To ensure coding reliability, inter-coder agreement was maintained by having a second researcher independently code a subset of the data. Discrepancies in coding were resolved through discussion and consensus, ensuring consistency and reliability of the findings Themes were derived iteratively, capturing the essence of participants' experiences while ensuring consistency with the study's phenomenological framework. The findings were synthesized into thematic clusters, reflecting the core meanings and insights of the phenomenon.

Ethics

Ethical approval was obtained from the relevant institutional review board, ensuring compliance with international and local ethical standards (C. Liu dkk., 2021). Participants provided written informed consent before participation, with assurances of anonymity and confidentiality throughout the study. Audio recordings and transcripts were securely stored, and identifying information was removed during analysis to protect participants' identities. The study followed the principles of the Declaration of Helsinki to uphold ethical rigor.

RESULTS AND DISCUSSION

Technical Complexity and the Necessity of Validation

Participants consistently emphasized the intricate technical challenges inherent in molecular modeling and computational pharmacology. The complexity of configuring simulation parameters and ensuring accurate predictions emerged as a critical aspect of their experience. One participant noted, "The docking results might show a high binding affinity, but when validated through in vitro assays, the pharmacological activity can be surprisingly low." This highlights the need for rigorous validation to bridge the gap between computational predictions and biological realities.

The technical hurdles were often compounded by software-specific dependencies. Participants expressed the necessity for tailored training to interpret complex data outputs, such as Gibbs free energy calculations, which frequently require nuanced understanding. As one researcher observed, "Molecular dynamics software simplifies predictions, but interpreting Gibbs free energy values remains a significant challenge." This underscores the dual nature of technological advancements, offering both opportunities and obstacles for researchers in this field.

The Role of Interdisciplinary Collaboration

Interdisciplinary collaboration was a recurring theme, reflecting the collective efforts required to navigate the complexities of computational pharmacology. Participants highlighted the integration of expertise from chemists, bioinformaticians, and pharmacologists as a cornerstone of their work. "Collaborating with bioinformaticians enables us to refine our models and address data gaps effectively," said one participant.

This collaborative environment not only enhanced the robustness of molecular simulations but also fostered a shared understanding of ligand-receptor interactions. Observations from laboratory settings corroborated this, revealing frequent team discussions about simulation parameter adjustments and the interpretation of molecular interactions. The collaborative nature of these endeavors emerged as a pivotal factor in achieving meaningful insights.

Balancing Technology with Practical Relevance

While computational tools were praised for their ability to expedite drug discovery processes, participants expressed caution regarding their limitations. The necessity of aligning in silico results with practical pharmacological relevance was a recurring concern. One participant articulated this

.

sentiment: "Computational methods are indispensable, but they cannot replace experimental validations. They are complementary, not standalone solutions."

The interplay between computational predictions and wet-lab experiments was viewed as essential for advancing the field. Many participants advocated for a balanced approach that integrates both methodologies, ensuring that computational insights are grounded in empirical evidence. This perspective underscores the evolving nature of computational pharmacology as a discipline that bridges theoretical and experimental paradigms.

The findings highlight the multifaceted experiences of researchers in computational pharmacology and molecular modeling, characterized by technical challenges, collaborative efforts, and the imperative for validation. These insights reflect the dynamic and interdisciplinary nature of the field, emphasizing the need for continuous innovation and integration to advance drug discovery processes. The themes identified provide a nuanced understanding of the lived experiences of researchers, offering valuable perspectives for refining methodologies and fostering cross-disciplinary collaborations.

Summary of Key Findings

This study uncovered the nuanced experiences of researchers in computational pharmacology, emphasizing the challenges of interpreting molecular simulations and the necessity for interdisciplinary collaboration (P. Liu dkk., 2022). These findings address the core questions posed in the introduction by highlighting the subjective dimensions of integrating computational tools into drug discovery workflows.

Contribution to Research Questions

The study provides valuable insights into the experiential and interpretative aspects of computational pharmacology (Mak dkk., 2024). It reveals that researchers face significant challenges in aligning computational predictions with biological relevance, requiring iterative validation and collaborative efforts. By exploring their lived experiences, the research demonstrates how technical complexity, such as parameter optimization in molecular dynamics, often demands tailored problem-solving and robust interdisciplinary dialogue. This contributes to a deeper understanding of how researchers navigate and make sense of these tools beyond their technical functionalities, offering a holistic perspective on their practical and intellectual engagement with computational pharmacology.

Relation to Literature and Theory

The findings align with prior research, such as Goodsell et al. (1998), which acknowledged the limitations of computational methods in bridging theoretical predictions with empirical validation. However, this study extends the literature by focusing on the interpretative experiences of researchers, a dimension often overlooked in quantitative analyses (Manivannan dkk., 2024). The emphasis on interdisciplinary collaboration complements theoretical frameworks like Koshland's (1958) principles of molecular interactions, which underscore the importance of contextualizing ligand-receptor dynamics. Furthermore, the challenges highlighted in this study resonate with critiques of quantitative approaches that fail to capture the subjective and relational aspects of scientific inquiry, underscoring the value of phenomenology in addressing this gap.

Implications of Findings

The findings of this study have significant scientific and practical implications for computational pharmacology and related fields. Scientifically, they emphasize the need for integrated frameworks that combine computational and experimental approaches to enhance the accuracy and applicability of drug discovery efforts (Na Takuathung dkk., 2021). The study highlights how interdisciplinary collaboration fosters a deeper understanding of molecular interactions, providing a roadmap for developing more robust and context-sensitive computational tools. On a professional level, the insights into researchers' experiences underscore the importance of tailored training programs to bridge the gap between theoretical knowledge and practical applications. Culturally and socially, these findings reflect the growing demand for collaborative and adaptive scientific practices in addressing complex global health challenges.

`

Limitations of the Study

Despite its contributions, this study has several limitations. The use of purposive sampling, while effective for targeting experienced participants, may limit the generalizability of findings to other contexts or less experienced populations (Qiu dkk., 2024). Additionally, the focus on subjective experiences, inherent in the phenomenological approach, means that the study does not account for broader organizational or systemic factors that might influence researchers' practices. The reliance on self-reported data may also introduce biases related to participants' perceptions and memory. These limitations suggest caution in extrapolating the findings beyond the immediate context of computational pharmacology.

Prospective Directions for Future Research

The findings open several avenues for future research. Subsequent studies could expand on this work by incorporating a larger and more diverse participant pool to explore variations in experiences across different research settings. Investigations into the systemic and institutional factors influencing computational pharmacology practices could provide a complementary perspective to the individual experiences captured here. Additionally, integrating phenomenological insights with quantitative analyses of computational efficacy could yield a more comprehensive understanding of the field. These directions have the potential to further bridge the gap between computational and experimental methodologies, advancing the efficacy and impact of drug discovery efforts.

CONCLUSION

This study explored the subjective experiences of researchers in computational pharmacology, addressing the complexities of integrating molecular modeling tools into the drug discovery process. The findings highlighted key themes, including the technical challenges of parameter optimization, the necessity of interdisciplinary collaboration, and the critical role of validating computational results with experimental data. These insights emphasize the importance of addressing these challenges to improve the alignment between computational predictions and experimental outcomes, which is essential for advancing drug discovery workflows.

These findings provide a deeper understanding of the human dimensions involved in computational workflows, bridging gaps left by prior studies that focused predominantly on quantitative metrics. By adopting a phenomenological approach, this research contributes to a more holistic appreciation of the field, emphasizing the value of lived experiences in advancing scientific practices. The study also underlines the need for more targeted training programs that specifically address the nuances of interpreting computational data, particularly with regard to molecular dynamics and parameter adjustments. These findings not only enhance methodological awareness but also offer practical recommendations for improving training and fostering collaboration in computational pharmacology. Future research could expand on this foundation by exploring broader institutional influences or integrating phenomenological insights with quantitative analyses to further enhance the efficacy of drug discovery processes.

CONFLICT OF INTEREST

This article has undergone an independent peer review process. The editor responsible for evaluating this article has no direct relationship with the author and has never collaborated on any prior publications. The review process was conducted by an editor who has no association with the author in terms of collaboration or conflicts of interest.

.

REFERENCES

Baba, M. Z., Subramanian, G., Chand, J., Wahedi, U., Varakumar, P., Jayanthi, K., Azeemuddin, M., Emran, T. B., & Nainu, F. (2024). Investigation of Scutellaria baicalensis for Potential Neuroprotective Effect on the Treatment of Parkinson's Disease. *Biointerface Research in Applied Chemistry*, *14*(2). Scopus. https://doi.org/10.33263/BRIAC142.027

Bian, Y.-M., He, X.-B., Jing, Y.-K., Wang, L.-R., Wang, J.-M., & Xie, X.-Q. (2019). Computational systems pharmacology analysis of cannabidiol: A combination of chemogenomics-knowledgebase network analysis and integrated in silico modeling and simulation. *Acta Pharmacologica Sinica*, *40*(3), 374–386. Scopus. https://doi.org/10.1038/s41401-018-0071-1

Devaraji, V., & Sivaraman, J. (2024). Exploring the potential of machine learning to design antidiabetic molecules: A comprehensive study with experimental validation. *Journal of Biomolecular Structure and Dynamics*, *42*(23), 13290–13311. Scopus. https://doi.org/10.1080/07391102.2023.2275176

Geevarghese, A. V., Emimmal, M. E. S., Elizabeth, I. C. V., Krishnan, P., Sumathi, S. M., & Perumal, T. (2024). Development of Phytoconstituents from Spathodea campanulata Flowers as Potential Antimalarial Agents. *Anti-Infective Agents*, *22*(3), 16–32. Scopus. https://doi.org/10.2174/0122113525275435231205111538

Guan, Y.-J., Yu, C.-Q., Li, L.-P., You, Z.-H., Ren, Z.-H., Pan, J., & Li, Y.-C. (2022). BNEMDI: A Novel MicroRNA–Drug Interaction Prediction Model Based on Multi-Source Information With a Large-Scale Biological Network. *Frontiers in Genetics*, *13*. Scopus. https://doi.org/10.3389/fgene.2022.919264

Hosseini, F. S., & Amanlou, M. (2020). Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. *Life Sciences*, *258*. Scopus. https://doi.org/10.1016/j.lfs.2020.118205

Ivanets, N. N., Svistunov, A. A., Chubarev, V. N., Kinkulkina, M. A., Tikhonova, Y. G., Syzrantsev, N. S., Sologova, S. S., Ignatyeva, N. V., Mutig, K., & Tarasov, V. V. (2021). Can molecular biology propose reliable biomarkers for diagnosing major depression? *Current Pharmaceutical Design*, *27*(2), 305–318. Scopus. https://doi.org/10.2174/1381612826666201124110437

Khan, D. A., Adhikary, T., Sultana, M. T., & Toukir, I. A. (2024). A comprehensive identification of potential molecular targets and small drugs candidate for melanoma cancer using bioinformatics and network-based screening approach. *Journal of Biomolecular Structure and Dynamics*, *42*(14), 7349–7369. Scopus. https://doi.org/10.1080/07391102.2023.2240409

Lekmine, S., Benslama, O., Tahraoui, H., Ola, M. S., Laouani, A., Kadi, K., Martín-García, A. I., & Ali, A. (2024). Anti-Cholinergic Effects of the Phenolic Extract from the Astragalus crenatus Plant: A Computational and Network Pharmacology Study. *Pharmaceuticals*, *17*(3). Scopus. https://doi.org/10.3390/ph17030348

Liu, C., Wang, S., Zheng, S., Xu, F., Cao, Z., Feng, X., Wang, Y., Xue, Q., Sun, N., & He, J. (2021). Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. *Frontiers in Immunology*, *12*. Scopus. https://doi.org/10.3389/fimmu.2021.782106

Liu, P., Han, B., Zhang, Y., & Wang, X. (2022). Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. *Computational Intelligence and Neuroscience*, *2022*. Scopus. https://doi.org/10.1155/2022/7102500

.

Mak, D. A., Dunn, S., Coombes, D., Carere, C. R., Allison, J. R., Nock, V., Hudson, A. O., & Dobson, R. C. J. (2024). Enzyme Kinetics Analysis: An online tool for analyzing enzyme initial rate data and teaching enzyme kinetics. *Biochemistry and Molecular Biology Education*, *52*(3), 348–358. Scopus. https://doi.org/10.1002/bmb.21823

Manivannan, H. P., Veeraraghavan, V. P., & Francis, A. P. (2024). Identification of molecular targets of Trigonelline for treating breast cancer through network pharmacology and bioinformatics-based prediction. *Molecular Diversity*, *28*(6), 3835–3857. Scopus. https://doi.org/10.1007/s11030-023-10780-x

Na Takuathung, M., Sakuludomkan, W., Teekachunhatean, S., & Koonrungsesomboon, N. (2021). Characteristics and research techniques associated with the journal impact factor and other key metrics in pharmacology journals. *Computation*, *9*(11). Scopus. https://doi.org/10.3390/computation9110116

Qiu, Y., Wang, Y., Lu, J., Zhu, Q., Jia, L., Lei, F., Shen, L., Jiang, L., & Wu, A. (2024). Synthesis, spectroscopic analysis, DFT, docking, MD and antioxidant activity of tetrahydrocurcumin. *Journal of Biomolecular Structure and Dynamics*, *42*(24), 13447–13459. Scopus. https://doi.org/10.1080/07391102.2023.2275189